Who are Progesterone Effervescent Vaginal Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Slynd, Natazia, Mifeprex, Ortho-Cept, Delalutin, Megace.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/progesterone-effervescent-vaginal-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Progesterone Effervescent Vaginal Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Progesterone Effervescent Vaginal Tablets (Progesterone Effervescent Vaginal Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progestin. Area: Reproductive Health / Obstetrics.

phase 3 Progestin Progesterone receptor (PR) Reproductive Health / Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Progesterone Effervescent Vaginal Tablets (Progesterone Effervescent Vaginal Tablets) — University of Alberta. Progesterone is a naturally occurring steroid hormone that binds to progesterone receptors to support luteal phase function and maintain pregnancy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Progesterone Effervescent Vaginal Tablets TARGET	Progesterone Effervescent Vaginal Tablets	University of Alberta	phase 3	Progestin	Progesterone receptor (PR)
Slynd	DROSPIRENONE	Exeltis Usa Inc	marketed	Progestin	Mineralocorticoid receptor	2019-01-01
Natazia	DIENOGEST	Mochida Pharmaceutical Co., Ltd.	marketed	Progestin	Progesterone receptor	2010-01-01
Mifeprex	MIFEPRISTONE	Corcept Therap	marketed	Progestin Antagonist [EPC]	Glucocorticoid receptor	2000-01-01
Ortho-Cept	DESOGESTREL	Merck & Co.	marketed	Progestin	Sex hormone-binding globulin	1992-01-01
Delalutin	HYDROXYPROGESTERONE CAPROATE	Bristol-Myers Squibb	marketed	Progestin	Corticosteroid-binding globulin	1975-01-01
Megace	MEGESTROL ACETATE	Bristol-Myers Squibb	marketed	Progestin	Glucocorticoid receptor	1971-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-01-30 — Natazia · 8153616 · US

Sponsor landscape (Progestin class)

· 2 drugs in this class
Trieu, Nguyen Thi, M.D. · 2 drugs in this class
Bristol-Myers Squibb · 2 drugs in this class
Baylor Research Institute · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Exeltis Usa Inc · 1 drug in this class
IBSA Institut Biochimique SA · 1 drug in this class
Hillel Yaffe Medical Center · 1 drug in this class
Fdn Consumer · 1 drug in this class
Bio Meds Pharmaceutica Ltda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Progesterone Effervescent Vaginal Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/progesterone-effervescent-vaginal-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing